Financial insights of BSGM

MyFinsight

For the quarter ending 2025-06-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Income Statement	2025-06-30	2024-09-30	2024-06-30
Revenue	0	-	13
Research and development	19	156	342
Depreciation and amortization	-	-	49
Impairment of long term assets	0	-	-
General and administrative	19,792	2,763	4,914
Depreciation and amortization	554	31	-
Total operating expenses	20,365	2,950	5,305
Loss from operations	-20,365	-2,950	-5,292
Other income (expense), net	-13	15	-2
Interest income, net	13	-	-5
Gain (loss) on settlement and forgiveness of debt	-3	1,021	1,388
Total other income (expense), net	-3	-	-
Loss before income taxes	-20,368	-1,914	-3,911
Income taxes (benefit)	0	-	-
Net loss	-20,368	-1,914	-3,911
Non-controlling interest	4	-	4
Net loss attributable to biosig technologies, inc	-20,372	-1,914	-3,915
Preferred stock deemed dividend	0	24	-
Preferred stock dividend	2	2	3
Net loss attributed to biosig technologies, inc. common shareholders	-20,374	-1,940	-3,918

Net loss per common share, basic	-0.74	-0.12	-0.3
Net loss per common share, diluted	-0.74	-0.12	-0.3
Weighted average number of common shares outstanding, basic	27,706,780	16,200,928	12,916,272
Weighted average number of common shares outstanding, diluted	27,706,780	16,200,928	12,916,272